Anti-aging studies have become one of the most researched studies, because of the demand. Everybody would want to look young and definitely feel sad for aging. Additionally, if anti-aging look comes along with a young feeling from within the body too, who would reject it. A startup based in Monterey, California, called Ambrosia is working on rejuvenating the whole body with a young look.
Ambrosia is starting a clinical trial to rejuvenate about 35 people by injecting them young people’s blood plasma. Ambrosia is taking forward the study of Harvard Stem Cell Institute by the researcher Amy Wagers. The study reveals that linking the circulatory system of young mice to old mice, facilitates rejuvenation in the old mice. This procedure is known as Parabiosis.
In parabiosis, two mice are surgically sewed together, exposing the old circulatory system to young blood. Which results in the better functioning of the weakened, enlarged hearts of older mice.
Blood carries messages, molecules and certain hormones from one cell another, besides carrying oxygen. Due to aging, blood as well as hormones undergoes change. There is an imbalance of factors required for the development of tissues and repairing of injuries, in the body because of aging. Therefore, blood is chosen as the main actor in the process of rejuvenating the old.
Ambrosia for its clinical trial is injecting young blood plasma unlike blood in parabiosis process. Youngblood plasma will be taken from people below the age of 25. It will also test the blood one month prior and after the transmission.
Ambrosia is, however receiving stringent criticisms on various grounds from certain researchers. The critics are mainly concerned with the methodology and benefits of such transfusions. Critics point out the pay-to-participate model of the trial, would result in the appearance of the unproven clinics all over. Another point of contention is regarding the procedure of the trail is ought to be carried on. There are neither control groups nor placebos used in a trail. Moreover, there are no well-accepted biomarkers for aging in blood.
Neuroscientist Tony Wyss-Coray, one of the scientists who led the 2014 Harvard Stem cell Institute study said, “There’s just no clinical evidence [that the treatment will be beneficial], and you’re basically abusing people’s trust and the public excitement around this.”
Taken all care, if this study proves to be successful would result in newer generation scientifically.